The Pipeline

TAVR shows promise, but renal denervation’s future unclear: What you need to know from ACC 2014

Vanessa Lo and Jake Kahane, Service Line Strategy Advisor

This past weekend, the American College of Cardiology’s 65th Annual Meeting took place in Washington, DC. Leading cardiovascular experts from around the world gathered to present on the latest advances in CV therapies as well as future innovations to improve patient care. Here are the top highlights from this year’s conference.

Promising future for TAVR efficacy and LOS

Two headlining TAVR trials and several discussions at TAVR-focused break-out sessions signaled a promising future for the TAVR technology’s efficacy and LOS. Results from the CoreValve High-Risk trial suggest that TAVR may be superior to surgery for some patients at high-risk for mortality during surgery.

Meanwhile, a head-to-head study from Europe comparing the Sapien XT device and CoreValve demonstrated higher device implantation success rates for patients receiving the Sapien XT, but panelists warned the audience to be careful when drawing conclusions.

Renal denervation results call for further investigation

For the first time ever, investigators presented the detailed results of Medtronic’s SYMPLICITY HTN-3 trial, which demonstrated that the renal denervation in treatment-resistant hypertensive patients failed to show a difference between the denervation group and sham-control group. 

In light of these results, experts stress the need for additional studies to identify the appropriate patient population and further understand the biological processes.

Radial PCI learning curve may be overstated

Radial access for endovascular procedures such as PCI can help reduce LOS, lower complication rates, and cut costs. Physicians and administrators have always pointed to the significant learning curve associated with transradial access. A developing body of evidence highlighted at ACC, however, suggests that we may have been overstating how “steep” this learning curve really is.

Future of aortic aneurysm care: PEVAR in the cath lab

Vascular experts presented on the potential for percutaneous endovascular abdominal aneurysm repair (PEVAR) to influence aortic aneurysm care in the future. With a less invasive approach, PEVAR results in a number of advantages, which suggest the potential to perform the procedure in the cath lab with local anesthesia rather than in the OR. However, obstacles such as misaligned reimbursement incentives prevent widespread PEVAR adoption.

More from ACC 2014

For more information on each highlight, please click the hyperlinked titles above to read more. For more information on our latest conference coverage, subscribe to The Pipeline or follow us on Twitter. And, if you are interested in a TAVR or interventional services assessment, please contact your Dedicated Advisor today.